Announcements Trials
Browse Landscape

Status

Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 325Lung Neoplasms 237Small Cell Lung Carcinoma 79Colorectal Neoplasms 30NSCLC 25Breast Neoplasms 22Neoplasms 16Adenocarcinoma of Lung 16Disease 15Neoplasm Metastasis 12Stomach Neoplasms 10Melanoma 10Ovarian Neoplasms 9Brain Neoplasms 9Uterine Cervical Neoplasms 8Triple Negative Breast Neoplasms 8Squamous Cell Carcinoma of Head and Neck 8Pleural Effusion, Malignant 8Motor Activity 8Mesothelioma, Malignant 8Head and Neck Neoplasms 8Esophageal Neoplasms 7Endometrial Neoplasms 7Multiple Pulmonary Nodules 6Mesothelioma 6Carcinoma, Hepatocellular 6Thymoma 5Small Cell Lung Cancer Extensive Stage 5SCLC, Extensive Stage 5Recurrence 5

Interventions

taletrectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Non-small Lung Cancer × Thoracic × Clear all
NCT07199010 2025-09-30

Real-world Study of Taletrectinib in Advanced ROS1+ NSCLC Following Entrectinib Progression

Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting
50 enrolled
Thoracic

Non-small Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡